Patent · US Active

Human prostate cell lines in cancer treatment

US8545835B2 · kind B2 · utility

0Cited by

5References

13Claims

0Family size

Assignee

Onyvax Limited · GB

Inventors

Angus Dalgleish · London, GB
Anthony Ian Walker · London, GB

Key dates

Filing date	Jan 17, 2012
Grant date	Oct 1, 2013
Priority date	—
Expiry date	Jan 17, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/884
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides methods and compositions for the treatment of primary, metastatic, and residual cancer in mammals, and more particularly, the use of materials such as whole cells and derivatives and portions thereof to stimulate the immune system to attack cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.